371 related articles for article (PubMed ID: 34834468)
1. Mechanisms Involved in Microglial-Interceded Alzheimer's Disease and Nanocarrier-Based Treatment Approaches.
Md S; Alhakamy NA; Alfaleh MA; Afzal O; Altamimi ASA; Iqubal A; Shaik RA
J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834468
[TBL] [Abstract][Full Text] [Related]
2. Signalling Pathways Involved in Microglial Activation in Alzheimer's Disease and Potential Neuroprotective Role of Phytoconstituents.
Ali MU; Anwar L; Ali MH; Iqubal MK; Iqubal A; Baboota S; Ali J
CNS Neurol Disord Drug Targets; 2024; 23(7):819-840. PubMed ID: 36567300
[TBL] [Abstract][Full Text] [Related]
3. Myricetin improves pathological changes in 3×Tg-AD mice by regulating the mitochondria-NLRP3 inflammasome-microglia channel by targeting P38 MAPK signaling pathway.
Liu P; Zhou Y; Shi J; Wang F; Yang X; Zheng X; Wang Y; He Y; Xie X; Pang X
Phytomedicine; 2023 Jul; 115():154801. PubMed ID: 37086707
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
5. The neurobiology and therapeutic potential of multi-targeting β-secretase, glycogen synthase kinase 3β and acetylcholinesterase in Alzheimer's disease.
Fronza MG; Alves D; Praticò D; Savegnago L
Ageing Res Rev; 2023 Sep; 90():102033. PubMed ID: 37595640
[TBL] [Abstract][Full Text] [Related]
6. The Role of Microglia in Retinal Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma.
Ramirez AI; de Hoz R; Salobrar-Garcia E; Salazar JJ; Rojas B; Ajoy D; López-Cuenca I; Rojas P; Triviño A; Ramírez JM
Front Aging Neurosci; 2017; 9():214. PubMed ID: 28729832
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan Alleviates Alzheimer's Disease-Related Neuropathologies and Cognitive Impairments.
Fu XX; Wei B; Cao HM; Duan R; Deng Y; Lian HW; Zhang YD; Jiang T
J Alzheimers Dis; 2023; 94(3):919-933. PubMed ID: 37355897
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the intersection of microglial activation and neuroinflammation in Alzheimer's disease from the perspective of ferroptosis.
Wang M; Tang G; Zhou C; Guo H; Hu Z; Hu Q; Li G
Chem Biol Interact; 2023 Apr; 375():110387. PubMed ID: 36758888
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.
Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N
Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3: a key player in microglia-mediated neuroinflammation and Alzheimer's disease.
Tan Y; Zheng Y; Xu D; Sun Z; Yang H; Yin Q
Cell Biosci; 2021 Apr; 11(1):78. PubMed ID: 33906678
[TBL] [Abstract][Full Text] [Related]
11. Sirtuins as Potential Therapeutic Targets for Mitigating Neuroinflammation Associated With Alzheimer's Disease.
Fernando KKM; Wijayasinghe YS
Front Cell Neurosci; 2021; 15():746631. PubMed ID: 34630044
[TBL] [Abstract][Full Text] [Related]
12. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.
Streit WJ; Braak H; Xue QS; Bechmann I
Acta Neuropathol; 2009 Oct; 118(4):475-85. PubMed ID: 19513731
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer's disease.
Thawkar BS; Kaur G
J Neuroimmunol; 2019 Jan; 326():62-74. PubMed ID: 30502599
[TBL] [Abstract][Full Text] [Related]
14. CD45RB is a novel molecular therapeutic target to inhibit Abeta peptide-induced microglial MAPK activation.
Zhu Y; Hou H; Nikolic WV; Ehrhart J; Rrapo E; Bickford P; Giunta B; Tan J
PLoS One; 2008 May; 3(5):e2135. PubMed ID: 18478117
[TBL] [Abstract][Full Text] [Related]
15. Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.
Lian H; Litvinchuk A; Chiang AC; Aithmitti N; Jankowsky JL; Zheng H
J Neurosci; 2016 Jan; 36(2):577-89. PubMed ID: 26758846
[TBL] [Abstract][Full Text] [Related]
16. Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models.
Iyaswamy A; Wang X; Krishnamoorthi S; Kaliamoorthy V; Sreenivasmurthy SG; Kumar Durairajan SS; Song JX; Tong BC; Zhu Z; Su CF; Liu J; Cheung KH; Lu JH; Tan JQ; Li HW; Wong MS; Li M
Redox Biol; 2022 May; 51():102280. PubMed ID: 35286997
[TBL] [Abstract][Full Text] [Related]
17. Role of p38/MAPKs in Alzheimer's disease: implications for amyloid beta toxicity targeted therapy.
Kheiri G; Dolatshahi M; Rahmani F; Rezaei N
Rev Neurosci; 2018 Dec; 30(1):9-30. PubMed ID: 29804103
[TBL] [Abstract][Full Text] [Related]
18. Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology.
Kamat PK; Kalani A; Rai S; Tota SK; Kumar A; Ahmad AS
Mol Neurobiol; 2016 Sep; 53(7):4548-62. PubMed ID: 26298663
[TBL] [Abstract][Full Text] [Related]
19. Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice.
Feng J; Wang JX; Du YH; Liu Y; Zhang W; Chen JF; Liu YJ; Zheng M; Wang KJ; He GQ
CNS Neurosci Ther; 2018 Dec; 24(12):1207-1218. PubMed ID: 29869390
[TBL] [Abstract][Full Text] [Related]
20. Isoorientin, a GSK-3β inhibitor, rescues synaptic dysfunction, spatial memory deficits and attenuates pathological progression in APP/PS1 model mice.
Tan X; Liang Z; Li Y; Zhi Y; Yi L; Bai S; Forest KH; Nichols RA; Dong Y; Li QX
Behav Brain Res; 2021 Feb; 398():112968. PubMed ID: 33069740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
